ATE110265T1 - Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums. - Google Patents

Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.

Info

Publication number
ATE110265T1
ATE110265T1 AT90908385T AT90908385T ATE110265T1 AT E110265 T1 ATE110265 T1 AT E110265T1 AT 90908385 T AT90908385 T AT 90908385T AT 90908385 T AT90908385 T AT 90908385T AT E110265 T1 ATE110265 T1 AT E110265T1
Authority
AT
Austria
Prior art keywords
anxiolytic
manufacture
sigma receptor
receptor ligands
sigma
Prior art date
Application number
AT90908385T
Other languages
English (en)
Inventor
John F W Keana
Eckard Weber
Original Assignee
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State filed Critical Oregon State
Application granted granted Critical
Publication of ATE110265T1 publication Critical patent/ATE110265T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
AT90908385T 1989-05-02 1990-05-02 Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums. ATE110265T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34649489A 1989-05-02 1989-05-02

Publications (1)

Publication Number Publication Date
ATE110265T1 true ATE110265T1 (de) 1994-09-15

Family

ID=23359655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90908385T ATE110265T1 (de) 1989-05-02 1990-05-02 Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.

Country Status (9)

Country Link
EP (1) EP0473671B1 (de)
JP (1) JPH05500798A (de)
AT (1) ATE110265T1 (de)
AU (1) AU642881B2 (de)
CA (1) CA2054211A1 (de)
DE (1) DE69011859T2 (de)
DK (1) DK0473671T3 (de)
ES (1) ES2057568T3 (de)
WO (1) WO1990014067A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312840A (en) * 1986-07-10 1994-05-17 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education Substituted guanidines having high binding to the sigma receptor and the use thereof
US5385946A (en) * 1986-07-10 1995-01-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Method for treating hypertension with disubstituted granidine compounds
CA2076664C (en) 1990-03-02 2004-01-13 Eckard Weber Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5262568A (en) * 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5574070A (en) * 1990-05-25 1996-11-12 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Substituted guanidines having high binding to the sigma receptor and the use thereof
US5847006A (en) * 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
US5741661A (en) * 1991-02-08 1998-04-21 Cambridge Neuroscience, Inc. Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
PT100115B (pt) * 1991-02-08 1999-06-30 Cambridge Neuroscience Inc Guanidinas substituidas e seus derivados uteis como moduladores de libertacao de neurotransmissores e ensaios de rastreio para de bloqueadores de libertacao de neurotransmissores
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
ZA943744B (en) * 1993-05-27 1995-04-26 Cambridge Neuroscience Inc Therapeutic substituted guanidines
JPH09505600A (ja) * 1993-11-22 1997-06-03 ケンブリッジ・ニューロサイエンス・インコーポレーテッド 治療用グアニジン類
CA2177081A1 (en) * 1993-11-23 1995-06-01 Graham J. Durant Therapeutic substituted guanidines
US7351743B1 (en) 1994-02-03 2008-04-01 Wyeth Therapeutic guanidines
US6143791A (en) * 1994-02-03 2000-11-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
EP0751767A4 (de) 1994-02-03 1997-12-10 Cambridge Neuroscience Inc Guanidine zur therapeutischen verwendung
US6787569B1 (en) 1994-02-03 2004-09-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
WO1995023132A1 (en) * 1994-02-23 1995-08-31 Cambridge Neuroscience, Inc. Blockers of ion channels and methods of use thereof
US6875759B1 (en) 1999-07-21 2005-04-05 Kadmus Pharmaceuticals Substituted guanidines and the use thereof
EP1749824A1 (de) 2005-08-03 2007-02-07 Neuro3D Benzodiazepinederivate, Herstellung und Verwendung als Arzneimittel
US9296697B2 (en) 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2879454A1 (en) 2012-07-19 2014-01-23 Drexel University Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
WO2019089902A1 (en) 2017-11-01 2019-05-09 Drexel University Compounds, compositions, and methods for treating diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709094A (en) * 1986-07-10 1987-11-24 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Sigma brain receptor ligands and their use

Also Published As

Publication number Publication date
DK0473671T3 (da) 1994-09-19
CA2054211A1 (en) 1990-11-03
EP0473671A4 (en) 1992-04-01
EP0473671A1 (de) 1992-03-11
JPH05500798A (ja) 1993-02-18
AU642881B2 (en) 1993-11-04
WO1990014067A3 (en) 1991-04-04
DE69011859T2 (de) 1994-12-15
DE69011859D1 (de) 1994-09-29
ES2057568T3 (es) 1994-10-16
AU5728790A (en) 1990-12-18
EP0473671B1 (de) 1994-08-24
WO1990014067A2 (en) 1990-11-29

Similar Documents

Publication Publication Date Title
ATE110265T1 (de) Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE1241T1 (de) Verfahren zur herstellung von 4,5-perfluor-1,3-dioxolanen.
DE59003791D1 (de) Verfahren zur Herstellung von 1,3,3-Trimethyl-5-oxo-cyclohexan-carbonitril.
DE69006911T2 (de) Verfahren zur Herstellung von 3,4-Dichloranilin.
DE59100547D1 (de) Verfahren zur Herstellung von linearen Polyamiden.
DE68914221T2 (de) Verfahren zur Herstellung von alifatischen alpha-omega-Diaminen, neue Verbindungen und deren Verwendung für die Haarfärbung.
DE3667960D1 (de) Verfahren zur herstellung von halogen-magnesium-alanat und dessen verwendung.
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
DE59005898D1 (de) Dinatriumsalz des Trimercapto-s-triazin-hexahydrats, Verfahren zu seiner Herstellung und Verwendung.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE69009394D1 (de) Verfahren zur Herstellung von 3-Cyano-3,5,5-trimethyl-1-cyclohexanon.
DE68922507D1 (de) Verfahren zur Herstellung von beta-2',2'-Difluornukleosiden.
DE69205601D1 (de) Verfahren zur Herstellung von 3-Cyano-3,5,5-trimethylcyclohexanon.
DE59103040D1 (de) Verfahren zur Herstellung von symmetrischen 2,2'-Methylen-bis-benztriazolylphenolen.
ATE43610T1 (de) Acino-foetale differenzierungsproteine verbunden mit krebs des pankreas, antiserum und monoklonale antikoerper gegen diese proteine und verfahren zu ihrer herstellung.
DE69010608T2 (de) Verfahren zur Herstellung von 1,1-Diarylethanen.
ES2096559T3 (es) Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.
DE58902684D1 (de) Verfahren zur herstellung von cyclischen n,n'-dimethylharnstoffen.
ATE115139T1 (de) Verfahren zur herstellung von 2,4-diamino-6- piperidinyl-pyrimidin-3-n-oxid.
DE69208636T2 (de) Verfahren zur herstellung von zidovudine
DE58906998D1 (de) Verfahren zur Herstellung von 4,5,6-Trichlorpyrimidin.
DE69011996D1 (de) Verfahren zur Herstellung von 1,4-Dihydroxy-2-arylnaphthoat.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee